Literature DB >> 34910794

CKD-MBD diagnosis: biochemical abnormalities.

Leandro Junior Lucca1, Rosa Maria Affonso Moysés2, Fabiana Rodrigues Hernandes3, José Edvanilson Barros Gueiros4.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34910794      PMCID： PMC8823911          DOI： 10.1590/2175-8239-JBN-2021-S102

Source DB:  PubMed          Journal:  J Bras Nefrol        ISSN： 0101-2800


× No keyword cloud information.
  40 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.

Authors:  Sharon M Moe; Miriam P Zidehsarai; Mary A Chambers; Lisa A Jackman; J Scott Radcliffe; Laurie L Trevino; Susan E Donahue; John R Asplin
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-23       Impact factor: 8.237

3.  High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death.

Authors:  Margaret J Blayney; Ronald L Pisoni; Jennifer L Bragg-Gresham; Juergen Bommer; Luis Piera; Akira Saito; Takashi Akiba; Marcia L Keen; Eric W Young; Friedrich K Port
Journal:  Kidney Int       Date:  2008-06-11       Impact factor: 10.612

4.  KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2017-06-21

5.  Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.

Authors:  Masafumi Fukagawa; Ryo Kido; Hirotaka Komaba; Yoshihiro Onishi; Takuhiro Yamaguchi; Takeshi Hasegawa; Noriaki Kurita; Shingo Fukuma; Tadao Akizawa; Shunichi Fukuhara
Journal:  Am J Kidney Dis       Date:  2013-10-08       Impact factor: 8.860

6.  Serum phosphate and mortality in patients with chronic kidney disease.

Authors:  Helen Eddington; Richard Hoefield; Smeeta Sinha; Constantina Chrysochou; Beverley Lane; Robert N Foley; Janet Hegarty; John New; Donal J O'Donoghue; Rachel J Middleton; Philip A Kalra
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

7.  Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients.

Authors:  M M Couttenye; P C D'Haese; V O Van Hoof; E Lemoniatou; W Goodman; G A Verpooten; M E De Broe
Journal:  Nephrol Dial Transplant       Date:  1996-06       Impact factor: 5.992

8.  A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.

Authors:  Sharon M Moe; Akber Saifullah; Robert E LaClair; Sohail A Usman; Zhangsheng Yu
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

9.  Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Authors:  Jack W Coburn; Hla M Maung; Logan Elangovan; Michael J Germain; Jill S Lindberg; Stuart M Sprague; Mark E Williams; Charles W Bishop
Journal:  Am J Kidney Dis       Date:  2004-05       Impact factor: 8.860

10.  Vitamin D levels and early mortality among incident hemodialysis patients.

Authors:  M Wolf; A Shah; O Gutierrez; E Ankers; M Monroy; H Tamez; D Steele; Y Chang; C A Camargo; M Tonelli; R Thadhani
Journal:  Kidney Int       Date:  2007-08-08       Impact factor: 10.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.